Videos

Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.

Robert Zeiser, MD, reviews the pathophysiology of graft versus host disease and explains its relationship to the desired graft versus leukemia effect.

Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.

In this companion article, Dr. Estelamari Rodriguez reflects on the role of reactive and proactive treatment approaches for the management of chemotherapy-induced myelosuppression in small cell lung cancer.

Yelena Ginzburg, MD, discusses a long-term goal of the use of rusfertide in patients with chronic polycythemia vera.

Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.

A broad review of CNS-related clinical trial data in the setting of HER2+ breast cancer and concurrent brain metastases.

Grzegorz S. Nowakowski, MD, presents the case of a woman with relapsed DLBLC and provides his initial impressions.

A brief discussion on treatment options available for patients with HER2+ metastatic breast cancer and brain metastases who progress on the HER2CLIMB regimen.

Sam S. Chang, MD, MBA, discusses unanswered research questions about histologic subtypes of bladder cancer.

Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.

Debra A. Patt, MD, PhD, MBA, discusses a study of digital health systems used at Texas Oncology locations and how it helps with remote communication between patients with cancer and clinicians.

Panelists center their discussion on a real-world patient case of nonmetastatic castration-resistant prostate cancer managed with surgery and adjuvant therapy.

Matthew T. Campbell, MD, discusses the results of a retrospective analysis of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation.

Experts provide comprehensive insight on prostate cancer, covering its prevalence, subtypes, and the systemic treatment armamentarium.

Vivek Subbiah, MD, discusses the adverse events that come with the use of kinase inhibitors to treat patients with thyroid cancer.

Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.

William J. Gradishar, MD, discusses the impact of new data on the National Comprehensive Cancer Network guidelines for patients with early-stage breast cancer.

Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.

Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.

Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.

Christopher Melani, MD, discusses the unmet needs remaining in the mantle cell lymphoma space.

Cristian Tomasetti, PhD, discusses the clinical questions that exist among physician who treat patient with stage II colon cancer.

Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Alexander Drilon, MD, discusses targeted therapies for the patients with NTRK gene fusion-positive cancers.

Courtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.

A review of the safety outcome data of venetoclax plus azacitidine from the VIALE-A trial.

Dr Courtney DiNardo details the dosing recommendations for venetoclax plus azacitidine and the importance of bone marrow assessments.

Dr Courtney DiNardo reviews the efficacy data from the VIALE-A trial and explains the rationale for combining venetoclax with azacitidine as a treatment option for patients with AML.

Centering discussion on a patient case of HER2+ breast cancer with brain metastases, experts consider optimal treatment regimens in this setting.